Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 35 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/12/2008


1.		Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-1694 CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9

Last Modified: 8/14/2008 First Published: 4/1/2000


2.		Phase III Randomized Study of Postoperative GM2-KLH and QS21 Vaccination Versus Observation in Patients With Primary Cutaneous Stage II Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 80				Other				EORTC-18961 BMS-CA152-003, NCT00005052

Last Modified: 6/1/1995


3.		Phase I/II Pilot Study of Vaccination with Tyrosinase Peptides or Proteins or Tyrosinase-KLH Conjugate plus QS-21 in High-Risk Stage III/IV Melanoma (Summary Last Modified 06/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				no age specified								MSKCC-94029 NCI-V94-0467

Last Modified: 1/1/1998


4.		Phase I/II Study of Vaccination with Tumor-Specific CML Breakpoint Peptides plus QS21 for Chronic Myelogenous Leukemia in Partial or Complete Remission (Summary Last Modified 01/1998)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				over 18				NCI				MSKCC-95029A3 NCI-H95-0683

Last Modified: 4/1/1994


5.		Phase II Study of Immunization Using Anti-Idiotypic MOAB BEC2 with QS21 Adjuvant in Melanoma Patients Disease-Free Following Surgery But at High Risk of Recurrence (Summary Last Modified 04/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								MSKCC-93087A1 NCI-V94-0348

Last Modified: 3/1/1995


6.		Phase II Pilot Study of Booster Vaccinations with GM2-KLH plus QS21 for Stage III/IV Melanoma (Summary Last Modified 03/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				any age								MSKCC-94009A1 NCI-V94-0458

Last Modified: 6/1/1995


7.		Phase II Pilot Study of Vaccination with GM2-KLH plus QS21 in Stage III/IV Melanoma (Summary Last Modified 06/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified				NCI				MSKCC-94041 NCI-H94-0471

Last Modified: 8/2/2007


8.		Phase II Randomized Study of Vaccination with GM-2 Ganglioside Conjugated to Keyhole Limpet Hemocyanin plus the Immunologic Adjuvant QS21 with vs without High-Dose Interferon alfa in High-Risk Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				E-2696 E2696

Last Modified: 1/1/2000


9.		Phase II Randomized Study Comparing Immunologic Responses of Stage II and III Colorectal Cancer Patients on Adjuvant Therapy Treated with 3H1 Anti-Idiotype Monoclonal Antibody Mixed with Sargramostim Versus 3H1 Anti-Idiotype Monoclonal Antibody Alum Precipitate Mixed with Sargramostim (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UKMC-95GI24CB NCI-H97-1184

Last Modified: 2/1/1999 First Published: 3/1/1998


10.		Phase II Study of Vaccination with Mucin Peptide (MUC-2) Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant Q21 in Patients with Prostate Cancer (Summary Last Modified 02/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MSKCC-97122 NCI-G98-1378

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute